PT3294769T - Tratamento para mieloma múltiplo (mm) - Google Patents

Tratamento para mieloma múltiplo (mm)

Info

Publication number
PT3294769T
PT3294769T PT167233493T PT16723349T PT3294769T PT 3294769 T PT3294769 T PT 3294769T PT 167233493 T PT167233493 T PT 167233493T PT 16723349 T PT16723349 T PT 16723349T PT 3294769 T PT3294769 T PT 3294769T
Authority
PT
Portugal
Prior art keywords
treatment
multiple myeloma
myeloma
Prior art date
Application number
PT167233493T
Other languages
English (en)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PT3294769T publication Critical patent/PT3294769T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
PT167233493T 2015-05-13 2016-05-13 Tratamento para mieloma múltiplo (mm) PT3294769T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15167597 2015-05-13

Publications (1)

Publication Number Publication Date
PT3294769T true PT3294769T (pt) 2021-04-13

Family

ID=53174925

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167233493T PT3294769T (pt) 2015-05-13 2016-05-13 Tratamento para mieloma múltiplo (mm)

Country Status (24)

Country Link
US (2) US10533057B2 (pt)
EP (1) EP3294769B1 (pt)
JP (2) JP7160533B2 (pt)
KR (1) KR20180008571A (pt)
CN (1) CN107614530A (pt)
AU (1) AU2016260895B2 (pt)
CA (1) CA2984464C (pt)
CY (1) CY1123982T1 (pt)
DK (1) DK3294769T3 (pt)
ES (1) ES2862708T3 (pt)
HR (1) HRP20210552T1 (pt)
HU (1) HUE054271T2 (pt)
IL (1) IL255552B (pt)
LT (1) LT3294769T (pt)
MX (1) MX380557B (pt)
PL (1) PL3294769T3 (pt)
PT (1) PT3294769T (pt)
RS (1) RS61668B1 (pt)
RU (1) RU2723047C2 (pt)
SG (1) SG11201708691VA (pt)
SI (1) SI3294769T1 (pt)
SM (1) SMT202100202T1 (pt)
WO (1) WO2016180958A1 (pt)
ZA (1) ZA201708386B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
CN110144008B (zh) 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
KR20250117714A (ko) * 2018-03-28 2025-08-05 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투약
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
KR20210104736A (ko) * 2018-12-14 2021-08-25 모르포시스 아게 항체 제형
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ-アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020194242A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with pomalidomide and dexamethasone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
WO1999062526A2 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
KR20140066259A (ko) 2004-02-06 2014-05-30 모르포시스 아게 항-cd38 인간 항체 및 그의 용도
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
JP5225069B2 (ja) * 2005-03-23 2013-07-03 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
AU2007281684C1 (en) * 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
WO2008037257A2 (en) * 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SMT202000031T1 (it) * 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
DK2621531T3 (en) * 2010-09-27 2017-02-27 Morphosys Ag ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL
US9738933B2 (en) * 2012-12-05 2017-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
US20150118251A1 (en) * 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2016022589A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
PH12017500442B1 (en) 2014-09-09 2023-05-24 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
HUE054271T2 (hu) * 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése

Also Published As

Publication number Publication date
RU2017137496A3 (pt) 2019-06-13
WO2016180958A1 (en) 2016-11-17
US11591406B2 (en) 2023-02-28
US20190048091A1 (en) 2019-02-14
DK3294769T3 (da) 2021-03-08
SI3294769T1 (sl) 2021-07-30
SMT202100202T1 (it) 2021-05-07
EP3294769B1 (en) 2021-01-13
US10533057B2 (en) 2020-01-14
JP2018515513A (ja) 2018-06-14
AU2016260895B2 (en) 2021-08-05
US20200079871A1 (en) 2020-03-12
CN107614530A (zh) 2018-01-19
CY1123982T1 (el) 2022-05-27
MX380557B (es) 2025-03-12
HRP20210552T1 (hr) 2021-05-14
RU2017137496A (ru) 2019-06-13
JP7160533B2 (ja) 2022-10-25
RU2723047C2 (ru) 2020-06-08
ZA201708386B (en) 2019-06-26
KR20180008571A (ko) 2018-01-24
IL255552A (en) 2018-01-31
HUE054271T2 (hu) 2021-08-30
JP2021130668A (ja) 2021-09-09
PL3294769T3 (pl) 2021-07-05
IL255552B (en) 2022-01-01
ES2862708T3 (es) 2021-10-07
RS61668B1 (sr) 2021-04-29
LT3294769T (lt) 2021-04-26
AU2016260895A1 (en) 2017-11-09
EP3294769A1 (en) 2018-03-21
CA2984464C (en) 2023-10-10
SG11201708691VA (en) 2017-11-29
MX2017014396A (es) 2018-03-23
CA2984464A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
SG11201705093UA (en) Composition for treating il-6-related diseases
GB2544294B (en) Goggles for snowsports
GB201500989D0 (en) Process
ZA201708386B (en) Treatment for multiple myeloma (mm)
IL278247B (en) mct4 inhibitors to treat the disease
IL254393A0 (en) Methods for treating diseases associated with pathological changes in protein
GB201502893D0 (en) Process
GB201502894D0 (en) Process
IL256116A (en) geometric
GB201502137D0 (en) Treatment
GB201522243D0 (en) Treatment
GB201501952D0 (en) Process
GB201500990D0 (en) Process
GB201501953D0 (en) Process
GB201501423D0 (en) Process
GB201519450D0 (en) Novel treatment
GB201502814D0 (en) Process
GB201604658D0 (en) Treatment for pain
GB201519331D0 (en) Treatment paradigm
GB201508841D0 (en) Treatment
GB201503606D0 (en) Process
PT3350149T (pt) Compostos terminados com[(2-etoxi-5-trans-1-propen-1-il)-fenoxil]
SG11201706885RA (en) Novel treatment method
GB201503008D0 (en) Treatment
GB201500277D0 (en) Process